CN101481352A - 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 - Google Patents
双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 Download PDFInfo
- Publication number
- CN101481352A CN101481352A CNA2008100003466A CN200810000346A CN101481352A CN 101481352 A CN101481352 A CN 101481352A CN A2008100003466 A CNA2008100003466 A CN A2008100003466A CN 200810000346 A CN200810000346 A CN 200810000346A CN 101481352 A CN101481352 A CN 101481352A
- Authority
- CN
- China
- Prior art keywords
- compound
- hydroxyl
- alkyl
- general formula
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 150000002148 esters Chemical class 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 24
- 150000001733 carboxylic acid esters Chemical group 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 17
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000004317 sodium nitrate Substances 0.000 claims description 9
- 235000010344 sodium nitrate Nutrition 0.000 claims description 9
- 229940001516 sodium nitrate Drugs 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims description 7
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 7
- 210000001772 blood platelet Anatomy 0.000 claims description 7
- 238000012546 transfer Methods 0.000 claims description 7
- 238000006193 diazotization reaction Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000020 Nitrocellulose Substances 0.000 claims description 5
- 229920001220 nitrocellulos Polymers 0.000 claims description 5
- 230000026731 phosphorylation Effects 0.000 claims description 5
- 238000006366 phosphorylation reaction Methods 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 101100041625 Arabidopsis thaliana SAC9 gene Proteins 0.000 claims description 4
- 102000009410 Chemokine receptor Human genes 0.000 claims description 4
- 108050000299 Chemokine receptor Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000409 cytokine receptor agonist Substances 0.000 claims description 4
- 238000004925 denaturation Methods 0.000 claims description 4
- 230000036425 denaturation Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000568 immunological adjuvant Substances 0.000 claims description 4
- 102000002467 interleukin receptors Human genes 0.000 claims description 4
- 108010093036 interleukin receptors Proteins 0.000 claims description 4
- 230000002934 lysing effect Effects 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000003929 acidic solution Substances 0.000 claims description 3
- 150000001448 anilines Chemical class 0.000 claims description 3
- 150000001728 carbonyl compounds Chemical class 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 230000003750 conditioning effect Effects 0.000 claims description 3
- 125000003963 dichloro group Chemical group Cl* 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 150000001412 amines Chemical group 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- 239000000430 cytokine receptor antagonist Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 150000002169 ethanolamines Chemical class 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000003637 basic solution Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000010534 mechanism of action Effects 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 description 38
- 102000036693 Thrombopoietin Human genes 0.000 description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- 238000001819 mass spectrum Methods 0.000 description 28
- 239000002994 raw material Substances 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
- 238000001035 drying Methods 0.000 description 19
- -1 methyl aceto acetate Chemical class 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 9
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 230000006837 decompression Effects 0.000 description 8
- 238000003810 ethyl acetate extraction Methods 0.000 description 8
- 235000010288 sodium nitrite Nutrition 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000001501 megacaryocyte Anatomy 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 5
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 206010043554 thrombocytopenia Diseases 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 4
- RBXVOQPAMPBADW-UHFFFAOYSA-N nitrous acid;phenol Chemical class ON=O.OC1=CC=CC=C1 RBXVOQPAMPBADW-UHFFFAOYSA-N 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229960001866 silicon dioxide Drugs 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- TZQWYTNGPYDSEM-UHFFFAOYSA-N 2,3-dihydro-1h-inden-5-ylhydrazine Chemical compound NNC1=CC=C2CCCC2=C1 TZQWYTNGPYDSEM-UHFFFAOYSA-N 0.000 description 3
- DFHGOCSWFGXYSQ-UHFFFAOYSA-N 2-bromo-4-fluoro-6-nitrophenol Chemical compound OC1=C(Br)C=C(F)C=C1[N+]([O-])=O DFHGOCSWFGXYSQ-UHFFFAOYSA-N 0.000 description 3
- VEJSIOPQKQXJAT-UHFFFAOYSA-N 2-bromo-6-nitrophenol Chemical compound OC1=C(Br)C=CC=C1[N+]([O-])=O VEJSIOPQKQXJAT-UHFFFAOYSA-N 0.000 description 3
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- FIPKSKMDTAQBDJ-UHFFFAOYSA-N 1-methyl-2,3-dihydro-1h-indene Chemical compound C1=CC=C2C(C)CCC2=C1 FIPKSKMDTAQBDJ-UHFFFAOYSA-N 0.000 description 2
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical group OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 2
- FFVBEUUHAYUHTK-UHFFFAOYSA-N 3-boronooxybenzoic acid Chemical compound OB(O)OC1=CC=CC(C(O)=O)=C1 FFVBEUUHAYUHTK-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical group [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- XDXWLKQMMKQXPV-QYQHSDTDSA-N eltrombopag Chemical compound CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 XDXWLKQMMKQXPV-QYQHSDTDSA-N 0.000 description 2
- 229960001069 eltrombopag Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- JHIUUQUYUPFOMR-UHFFFAOYSA-N 1-methyl-2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=C2C(C)CCC2=C1 JHIUUQUYUPFOMR-UHFFFAOYSA-N 0.000 description 1
- LEWZOBYWGWKNCK-UHFFFAOYSA-N 2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=C2CCCC2=C1 LEWZOBYWGWKNCK-UHFFFAOYSA-N 0.000 description 1
- PYHQGYGKYFNCMW-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)benzamide Chemical class NC(=O)C1=CC=CC=C1C1=NC=CS1 PYHQGYGKYFNCMW-UHFFFAOYSA-N 0.000 description 1
- MEYRABVEYCFHHB-UHFFFAOYSA-N 2-bromo-4-fluorophenol Chemical compound OC1=CC=C(F)C=C1Br MEYRABVEYCFHHB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SDCPFJIHUUMVDR-UHFFFAOYSA-N 4-boronooxybenzoic acid Chemical compound OB(O)OC1=CC=C(C(O)=O)C=C1 SDCPFJIHUUMVDR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700022598 Ovis aries megapoietin Proteins 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 150000004753 Schiff bases Chemical group 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 102100034195 Thrombopoietin Human genes 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000034311 endomitotic cell cycle Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 229960003231 thioacetazone Drugs 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100003466A CN101481352A (zh) | 2008-01-10 | 2008-01-10 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
| US12/812,119 US8367710B2 (en) | 2008-01-10 | 2009-01-04 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof |
| EP09703490.4A EP2236500B1 (en) | 2008-01-10 | 2009-01-04 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof |
| MX2010007553A MX2010007553A (es) | 2008-01-10 | 2009-01-04 | Derivados de azopirazolona biciclo-sustituidos, procedimiento de preparacion y uso farmaceutico de los mismos. |
| UAA201008616A UA101172C2 (ru) | 2008-01-10 | 2009-01-04 | Бициклозамещенные пиразолоназопроизводные, способ их получения и фармацевтическое применение |
| PCT/CN2009/000001 WO2009092276A1 (zh) | 2008-01-10 | 2009-01-04 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
| AU2009207966A AU2009207966B2 (en) | 2008-01-10 | 2009-01-04 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof |
| ES09703490.4T ES2533366T3 (es) | 2008-01-10 | 2009-01-04 | Derivados azoicos de pirazolona biciclo-sustituidos, procedimiento de preparacion y utilización farmacéutica de los mismos |
| BRPI0907234-9A BRPI0907234B1 (pt) | 2008-01-10 | 2009-01-04 | Derivados de pirazolona-azo biciclo-substituído, seu uso, seu intermediário e seus processos de preparação, composição farmacêutica e deu uso |
| PT97034904T PT2236500E (pt) | 2008-01-10 | 2009-01-04 | Derivados azo de pirazolona substituída com biciclo, processo para a sua preparação e a sua utilização farmacêutica |
| HK10102994.0A HK1134818B (en) | 2008-01-10 | 2009-01-04 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof |
| CA2711535A CA2711535C (en) | 2008-01-10 | 2009-01-04 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof |
| KR1020107017630A KR101556808B1 (ko) | 2008-01-10 | 2009-01-04 | 비씨클로-치환된 피라졸론 아조 유도체, 그 제조 방법 및 약학적 용도 |
| CN2009800001980A CN101679286B (zh) | 2008-01-10 | 2009-01-04 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
| RU2010127786/04A RU2488582C2 (ru) | 2008-01-10 | 2009-01-04 | Бициклозамещенные азопроизводные пиразолона, способ их получения и фармацевтическое применение |
| JP2010541680A JP5441269B2 (ja) | 2008-01-10 | 2009-01-04 | ビシクロ置換ピラゾロン−アゾ誘導体、その調製プロセス及び製薬学的使用 |
| ZA2010/04794A ZA201004794B (en) | 2008-01-10 | 2010-07-07 | Bicyclo-substituted pyrazolon azo derivatives,preparation process and pharmaceutical use thereof |
| US13/742,633 US20130123507A1 (en) | 2008-01-10 | 2013-01-16 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100003466A CN101481352A (zh) | 2008-01-10 | 2008-01-10 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101481352A true CN101481352A (zh) | 2009-07-15 |
Family
ID=40878665
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100003466A Pending CN101481352A (zh) | 2008-01-10 | 2008-01-10 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
| CN2009800001980A Active CN101679286B (zh) | 2008-01-10 | 2009-01-04 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009800001980A Active CN101679286B (zh) | 2008-01-10 | 2009-01-04 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8367710B2 (https=) |
| EP (1) | EP2236500B1 (https=) |
| JP (1) | JP5441269B2 (https=) |
| KR (1) | KR101556808B1 (https=) |
| CN (2) | CN101481352A (https=) |
| AU (1) | AU2009207966B2 (https=) |
| BR (1) | BRPI0907234B1 (https=) |
| CA (1) | CA2711535C (https=) |
| ES (1) | ES2533366T3 (https=) |
| MX (1) | MX2010007553A (https=) |
| PT (1) | PT2236500E (https=) |
| RU (1) | RU2488582C2 (https=) |
| UA (1) | UA101172C2 (https=) |
| WO (1) | WO2009092276A1 (https=) |
| ZA (1) | ZA201004794B (https=) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010142137A1 (zh) * | 2009-06-11 | 2010-12-16 | 江苏恒瑞医药股份有限公司 | 双环取代吡唑酮偶氮类衍生物的盐，及其制备方法和应用 |
| WO2013152683A1 (zh) * | 2012-04-11 | 2013-10-17 | 齐鲁制药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及用途 |
| CN104592033A (zh) * | 2014-12-30 | 2015-05-06 | 杭州和泽医药科技有限公司 | 一种艾曲波帕关键中间体的合成方法 |
| WO2018133818A1 (zh) * | 2017-01-19 | 2018-07-26 | 江苏恒瑞医药股份有限公司 | 一种双环取代吡唑酮偶氮类衍生物的制备方法及其中间体 |
| CN110028497A (zh) * | 2018-01-11 | 2019-07-19 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素模拟物的乙醇胺盐的结晶形式及制备方法 |
| WO2020143593A1 (zh) * | 2019-01-08 | 2020-07-16 | 江苏恒瑞医药股份有限公司 | 双环取代吡唑酮偶氮类衍生物的给药方案 |
| CN112062699A (zh) * | 2020-11-13 | 2020-12-11 | 苏州开元民生科技股份有限公司 | 一种邻氨基苯硫酚的制备方法 |
| CN112220766A (zh) * | 2016-01-22 | 2021-01-15 | 江苏恒瑞医药股份有限公司 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
| WO2025140275A1 (zh) * | 2023-12-25 | 2025-07-03 | 江苏恒瑞医药股份有限公司 | 取代吡唑啉偶氮衍生物的磷酸酯化合物或其可药用盐 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| JP5704073B2 (ja) * | 2009-10-23 | 2015-04-22 | 日産化学工業株式会社 | 縮環へテロ環化合物及びトロンボポエチンレセプター活性化剤 |
| CN103724206A (zh) * | 2014-01-17 | 2014-04-16 | 青岛农业大学 | 化合物2-溴-4-氟-6-硝基苯酚的制备方法和农用生物活性 |
| WO2015111085A2 (en) * | 2014-01-27 | 2015-07-30 | Cadila Healthcare Limited | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof |
| US9849077B2 (en) | 2014-03-10 | 2017-12-26 | Mary Kay Inc. | Skin lightening compositions |
| CN106994120B (zh) * | 2016-01-22 | 2021-05-14 | 江苏恒瑞医药股份有限公司 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
| WO2022228551A1 (zh) * | 2021-04-30 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素受体激动剂的给药方案 |
| US20250144077A1 (en) * | 2022-01-25 | 2025-05-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Dosage regimen for thrombopoietin receptor agonist |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB775216A (en) * | 1954-02-23 | 1957-05-22 | Sandoz Ltd | Improvements in or relating to monoazo dyestuffs of the benzene-azo-pyrazolone series and their chromium-complex compounds |
| GB806709A (en) * | 1955-04-22 | 1958-12-31 | Bayer Ag | Monoazo dyestuffs of the benzene-azo-pyrazolone series and metal complexes thereof |
| TR199701526T1 (xx) | 1995-06-07 | 1998-03-21 | Glaxo Group Limited | Bir trombopoietin resept�r�ne ba�lanan peptitler ve bile�ikler. |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| JPH111477A (ja) | 1997-06-12 | 1999-01-06 | Hokuriku Seiyaku Co Ltd | １，４−ベンゾジアゼピン誘導体及びその用途 |
| AU9265698A (en) | 1997-09-02 | 1999-03-22 | Boehringer Mannheim Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing themand their use for the treatment and prevention of thrombocytopaenia and anaemia |
| JP2002529502A (ja) | 1998-11-17 | 2002-09-10 | スミスクライン・ビーチャム・コーポレイション | 血小板減少症の治療法 |
| WO2000039773A1 (de) | 1998-12-14 | 2000-07-06 | Mannesmann Ag | Verfahren zur übertragung von verkehrsinformationen |
| GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
| KR20020069183A (ko) | 1999-07-26 | 2002-08-29 | 시오노기세이야쿠가부시키가이샤 | 트롬보포이에틴 작동성을 나타내는 의약 조성물 |
| EP1213965B1 (en) | 1999-09-10 | 2006-01-18 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| WO2001034585A1 (en) | 1999-11-05 | 2001-05-17 | Smithkline Beecham Corporation | Semicarbazone derivatives and their use as thrombopoietin mimetics |
| AU2079901A (en) | 1999-12-06 | 2001-06-12 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| CY2010012I2 (el) * | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| TWI280128B (en) * | 2002-05-22 | 2007-05-01 | Smithkline Beecham Corp | 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| EP2387998A1 (en) * | 2003-04-29 | 2011-11-23 | Glaxosmithkline LLC | Methods for treating degenerative diseases/injuries |
| DE602004019685D1 (de) | 2003-12-26 | 2009-04-09 | Allergan Inc | DISUBSTITUIERTE CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR(Gamma)-RETINOIDREZEPTOR |
| JP4518819B2 (ja) * | 2004-03-17 | 2010-08-04 | 富士フイルム株式会社 | アゾ化合物 |
| AU2005314788B2 (en) * | 2004-12-14 | 2011-09-22 | Nissan Chemical Industries, Ltd. | Amide compound and thrombopoietin receptor activator |
| JP2009511603A (ja) * | 2005-10-13 | 2009-03-19 | スミスクライン・ビーチャム・コーポレイション | 貯蔵中の血小板の有効性を維持する方法 |
| CA2630234A1 (en) * | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
-
2008
- 2008-01-10 CN CNA2008100003466A patent/CN101481352A/zh active Pending
-
2009
- 2009-01-04 ES ES09703490.4T patent/ES2533366T3/es active Active
- 2009-01-04 PT PT97034904T patent/PT2236500E/pt unknown
- 2009-01-04 WO PCT/CN2009/000001 patent/WO2009092276A1/zh not_active Ceased
- 2009-01-04 US US12/812,119 patent/US8367710B2/en active Active
- 2009-01-04 AU AU2009207966A patent/AU2009207966B2/en active Active
- 2009-01-04 CA CA2711535A patent/CA2711535C/en active Active
- 2009-01-04 CN CN2009800001980A patent/CN101679286B/zh active Active
- 2009-01-04 EP EP09703490.4A patent/EP2236500B1/en active Active
- 2009-01-04 MX MX2010007553A patent/MX2010007553A/es active IP Right Grant
- 2009-01-04 UA UAA201008616A patent/UA101172C2/ru unknown
- 2009-01-04 BR BRPI0907234-9A patent/BRPI0907234B1/pt active IP Right Grant
- 2009-01-04 KR KR1020107017630A patent/KR101556808B1/ko active Active
- 2009-01-04 JP JP2010541680A patent/JP5441269B2/ja active Active
- 2009-01-04 RU RU2010127786/04A patent/RU2488582C2/ru active
-
2010
- 2010-07-07 ZA ZA2010/04794A patent/ZA201004794B/en unknown
-
2013
- 2013-01-16 US US13/742,633 patent/US20130123507A1/en not_active Abandoned
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010142137A1 (zh) * | 2009-06-11 | 2010-12-16 | 江苏恒瑞医药股份有限公司 | 双环取代吡唑酮偶氮类衍生物的盐，及其制备方法和应用 |
| CN102159217A (zh) * | 2009-06-11 | 2011-08-17 | 江苏恒瑞医药股份有限公司 | 双环取代吡唑酮偶氮类衍生物的盐,及其制备方法和应用 |
| CN102159217B (zh) * | 2009-06-11 | 2012-10-03 | 江苏恒瑞医药股份有限公司 | 双环取代吡唑酮偶氮类衍生物的盐,及其制备方法和应用 |
| US8642637B2 (en) | 2009-06-11 | 2014-02-04 | Jiangsu Hengrui Medicine Co., Ltd. | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof |
| US9120762B2 (en) | 2009-06-11 | 2015-09-01 | Jiangsu Hengrui Medicine Co., Ltd. | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof |
| WO2013152683A1 (zh) * | 2012-04-11 | 2013-10-17 | 齐鲁制药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及用途 |
| CN103360317A (zh) * | 2012-04-11 | 2013-10-23 | 齐鲁制药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及用途 |
| CN103360317B (zh) * | 2012-04-11 | 2016-12-14 | 齐鲁制药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及用途 |
| CN104592033A (zh) * | 2014-12-30 | 2015-05-06 | 杭州和泽医药科技有限公司 | 一种艾曲波帕关键中间体的合成方法 |
| CN112220766A (zh) * | 2016-01-22 | 2021-01-15 | 江苏恒瑞医药股份有限公司 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
| CN112220766B (zh) * | 2016-01-22 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
| CN108884052A (zh) * | 2017-01-19 | 2018-11-23 | 江苏恒瑞医药股份有限公司 | 一种双环取代吡唑酮偶氮类衍生物的制备方法及其中间体 |
| WO2018133818A1 (zh) * | 2017-01-19 | 2018-07-26 | 江苏恒瑞医药股份有限公司 | 一种双环取代吡唑酮偶氮类衍生物的制备方法及其中间体 |
| TWI762556B (zh) * | 2017-01-19 | 2022-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種雙環取代吡唑酮偶氮類衍生物的製備方法及其中間體 |
| CN108884052B (zh) * | 2017-01-19 | 2025-07-11 | 江苏恒瑞医药股份有限公司 | 一种双环取代吡唑酮偶氮类衍生物的制备方法及其中间体 |
| CN110028497A (zh) * | 2018-01-11 | 2019-07-19 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素模拟物的乙醇胺盐的结晶形式及制备方法 |
| CN110028497B (zh) * | 2018-01-11 | 2020-11-17 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素模拟物的乙醇胺盐的结晶形式及制备方法 |
| WO2020143593A1 (zh) * | 2019-01-08 | 2020-07-16 | 江苏恒瑞医药股份有限公司 | 双环取代吡唑酮偶氮类衍生物的给药方案 |
| CN112062699A (zh) * | 2020-11-13 | 2020-12-11 | 苏州开元民生科技股份有限公司 | 一种邻氨基苯硫酚的制备方法 |
| WO2025140275A1 (zh) * | 2023-12-25 | 2025-07-03 | 江苏恒瑞医药股份有限公司 | 取代吡唑啉偶氮衍生物的磷酸酯化合物或其可药用盐 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5441269B2 (ja) | 2014-03-12 |
| BRPI0907234B1 (pt) | 2021-08-10 |
| JP2011509263A (ja) | 2011-03-24 |
| PT2236500E (pt) | 2015-04-07 |
| RU2010127786A (ru) | 2012-02-20 |
| KR101556808B1 (ko) | 2015-10-01 |
| CA2711535C (en) | 2015-12-15 |
| BRPI0907234A2 (pt) | 2020-08-04 |
| KR20100120141A (ko) | 2010-11-12 |
| ES2533366T3 (es) | 2015-04-09 |
| CN101679286A (zh) | 2010-03-24 |
| US20100316601A1 (en) | 2010-12-16 |
| RU2488582C2 (ru) | 2013-07-27 |
| WO2009092276A1 (zh) | 2009-07-30 |
| EP2236500B1 (en) | 2014-12-24 |
| HK1134818A1 (en) | 2010-05-14 |
| AU2009207966A1 (en) | 2009-07-30 |
| MX2010007553A (es) | 2010-10-04 |
| EP2236500A1 (en) | 2010-10-06 |
| CA2711535A1 (en) | 2009-07-30 |
| EP2236500A4 (en) | 2012-08-22 |
| CN101679286B (zh) | 2011-06-08 |
| UA101172C2 (ru) | 2013-03-11 |
| US20130123507A1 (en) | 2013-05-16 |
| AU2009207966B2 (en) | 2013-03-21 |
| US8367710B2 (en) | 2013-02-05 |
| ZA201004794B (en) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101481352A (zh) | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 | |
| JP4488663B2 (ja) | トロンボポイエチン模倣物 | |
| CN101636397B (zh) | 脲类化合物、其制备方法及其医药用途 | |
| CN113811300A (zh) | Tead转录因子的新型小分子抑制剂 | |
| CN102159217B (zh) | 双环取代吡唑酮偶氮类衍生物的盐,及其制备方法和应用 | |
| CN101778840A (zh) | ((1s)-1-(((2s)-2-(5-(4’-(2-((2s)-1-((2s)-2-((甲氧羰基)氨基)-3-甲基丁酰基)-2-吡咯烷基)-1h-咪唑-5-基)-4-联苯基)-1h-咪唑-2-基)-1-吡咯烷基)羰基)-2-甲基丙基)氨基甲酸甲酯二盐酸盐的晶型 | |
| HU230387B1 (hu) | TPO mimetikumként alkalmazható 3-{N'-[1-(3,4-dimetil-fenil)-3-metil-5-oxo-1,5-dihidro-4-pirazolilidén]hidrazino}-2-hidroxi-3'-(5-tetrazolil)-bifenil | |
| WO2000035446A1 (en) | Thrombopoietin mimetics | |
| JP2007509037A (ja) | アシルヒドラゾン誘導体ならびにキナーゼシグナル伝達の阻害、調節および／または調整におけるそれらの使用 | |
| JP2006501164A (ja) | トロンボポエチン疑似体 | |
| CN103360317B (zh) | 双环取代吡唑酮偶氮类衍生物、其制备方法及用途 | |
| CN101928281A (zh) | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 | |
| CN1850779B (zh) | β-榄香烯含氮衍生物及其制备方法和用途 | |
| JP2023550380A (ja) | 重水素修飾チエノピリドン化合物 | |
| WO2010096395A1 (en) | Amides as kinase inhibitors | |
| CN101514179A (zh) | 吲哚酮亚乙基肼羰基化合物、其制备方法及其在医药上的应用 | |
| JP2009516658A (ja) | ３，６−ジヒドロ−２−オキソ−６ｈ−１，３，４−チアジアジン誘導体 | |
| JP4477010B2 (ja) | タンパク質チロシンホスファターゼ阻害剤としてのジアミノピロロキナゾリン化合物 | |
| AU2006309576B2 (en) | Ortho-substituted aniline derivative and antioxidant drug | |
| JP7266090B2 (ja) | 新規なｎ－（イソプロピル－トリアゾリル）ピリジニル）－ヘテロアリール－カルボキサミド誘導体及びその用途 | |
| AU2006227101A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
| CA3136345A1 (en) | Hsp90 inhibitors and uses thereof | |
| US12552768B2 (en) | Pyridinylpyrazole derivative or pharmaceutically acceptable salt thereof and use thereof | |
| CN100334088C (zh) | 作为蛋白质酪氨酸磷酸酶抑制剂的二氨基吡咯并喹唑啉化合物 | |
| KR102734259B1 (ko) | 피리디닐 피라졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090715 |